Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May 8;125(18):2222-31.
doi: 10.1161/CIRCULATIONAHA.111.067827. Epub 2012 Apr 11.

Metabolite profiling identifies pathways associated with metabolic risk in humans

Affiliations

Metabolite profiling identifies pathways associated with metabolic risk in humans

Susan Cheng et al. Circulation. .

Abstract

Background: Although metabolic risk factors are known to cluster in individuals who are prone to developing diabetes mellitus and cardiovascular disease, the underlying biological mechanisms remain poorly understood.

Methods and results: To identify pathways associated with cardiometabolic risk, we used liquid chromatography/mass spectrometry to determine the plasma concentrations of 45 distinct metabolites and to examine their relation to cardiometabolic risk in the Framingham Heart Study (FHS; n=1015) and the Malmö Diet and Cancer Study (MDC; n=746). We then interrogated significant findings in experimental models of cardiovascular and metabolic disease. We observed that metabolic risk factors (obesity, insulin resistance, high blood pressure, and dyslipidemia) were associated with multiple metabolites, including branched-chain amino acids, other hydrophobic amino acids, tryptophan breakdown products, and nucleotide metabolites. We observed strong associations of insulin resistance traits with glutamine (standardized regression coefficients, -0.04 to -0.22 per 1-SD change in log-glutamine; P<0.001), glutamate (0.05 to 0.14; P<0.001), and the glutamine-to-glutamate ratio (-0.05 to -0.20; P<0.001) in the discovery sample (FHS); similar associations were observed in the replication sample (MDC). High glutamine-to-glutamate ratio was associated with lower risk of incident diabetes mellitus in FHS (odds ratio, 0.79; adjusted P=0.03) but not in MDC. In experimental models, administration of glutamine in mice led to both increased glucose tolerance (P=0.01) and decreased blood pressure (P<0.05).

Conclusions: Biochemical profiling identified circulating metabolites not previously associated with metabolic traits. Experimentally interrogating one of these pathways demonstrated that excess glutamine relative to glutamate, resulting from exogenous administration, is associated with reduced metabolic risk in mice.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs. Larson, Vasan, Gerszten, and Wang are named as co-inventors on a patent application to the US Patent Office pertaining to metabolite predictors of diabetes.

Figures

Figure 1
Figure 1
Beta coefficient and P values generated from age- and sex-adjusted regression analyses of the relation of each metabolite (standardized and log transformed) with insulin resistance phenotypes and metabolic traits (standardized) in the FHS sample.
Figure 2
Figure 2
Experimental results. (A) Mean (± standard error) area under the curve of serial glucose levels measured after intraperitoneal glucose tolerance test in mice treated for 8 weeks with dietary glutamine, glutamate, or standard chow alone (control). (B) Mean (± standard error) measures of glutamine and citrulline are shown in mice treated with dietary glutamine, glutamate, or standard chow alone (control). (C) Mean (± standard error) measures of systolic, diastolic, and mean blood pressure measurements are shown for mice following either intraperitoneal injection of glutamine plus saline (glutamine) or saline alone (control). (D) Mean (± standard error) measures of glutamine and citrulline are shown for mice following either intraperitoneal injection of glutamine plus saline (glutamine) or saline alone (control).

References

    1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752. - PubMed
    1. Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes. 2002;51:3069–3076. - PubMed
    1. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–419. - PubMed
    1. Sundstrom J, Vallhagen E, Riserus U, Byberg L, Zethelius B, Berne C, Lind L, Ingelsson E. Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care. 2006;29:1673–1674. - PubMed
    1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359. - PubMed

Publication types

MeSH terms